MediWound Ltd. (MDWD) Form 424B5 — Nov 3, 2026
MediWound filed a preliminary 424B5 prospectus supplement for an underwritten offering of ordinary shares, with H.C. Wainwright as sole book-running manager and a 30-day greenshoe of up to 15%. Pricing terms and share counts are blank pending pricing; the last reported sale price was $13.50 on November 2, 2026, against a net tangible book value of $2.76 per share, and the company warns of immediate and substantial dilution. The filing also pre-announced preliminary Q3 2026 results: revenue of approximately $3.6 million, down from $5.4 million a year ago due to lower U.S.
Key figures
- Revenue
- 3600000
- Revenue Yoy
- -33% (Q3 2026 preliminary ~$3.6M vs $5.4M Q3 2025)
- Cash Position
- 28400000
- Offering Price
- blank in preliminary filing; last reported sale price $13.50 (Nov 2, 2026)
- Shares Outstanding
- 13010217
- Do W award
- $3.3 million additional non-dilutive funding; $21.8M total program budget
- Option wa shares
- 1479362
- Greenshoe percent
- up to 15%
- Cash year end 2025
- 53600000
- Value trial target
- 216 patients at ~40 sites; interim reassessment/enrollment completion end of Q1 2027
- Outstanding warrants
- 2125828
- Prior year q3 revenue
- 5400000
- Option wa exercise price
- 15.79
- Net tangible book value per share
- 2.76
- Outstanding warrant exercise price
- $13.475 (expiring Nov 27, 2026)
- Warrant option exercise proceeds q3
- 1200000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.